3,654 results match your criteria AIDS-Related Lymphomas

The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma.

Infect Drug Resist 2021 18;14:1105-1113. Epub 2021 Mar 18.

Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, People's Republic of China.

Objective: Many studies have suggested that indexes of nutritional status, such as body mass index (BMI), serum albumin (ALB), serum pre-albumin (PA), and hemoglobin, may be used as risk factors for the prognosis of HIV or lymphoma. Therefore, this study aimed to retrospectively analyze and explore the value of nutritional status in the prognostic assessment of patients with AIDS-related lymphoma (ARL).

Methods: In this retrospective study, the clinical data of 69 patients with ARL were collected. Read More

View Article and Full-Text PDF

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas.

AIDS 2021 05;35(6):861-868

Centre Hospitalier de Versailles, Service d'Hémato-Oncologie, Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Le Chesnay.

Objectives: The value of Epstein-Barr virus (EBV) biomarkers on the prognosis of HIV-related non-Hodgkin's lymphoma (NHL) has been poorly explored in the combined antiretroviral therapy (cART) era.

Design: We evaluated EBV DNA load and EBV antibodies in HIV-NHL patients enrolled in the French ANRS-CO16 Lymphovir Cohort between 2008 and 2015.

Methods: Whole blood and plasma EBV DNA load and serological profiles were analyzed in 76 HIV-infected patients at diagnosis of NHL and 6 months after the initiation of chemotherapy. Read More

View Article and Full-Text PDF

The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination.

Front Immunol 2021 25;12:638872. Epub 2021 Feb 25.

Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

CXCL13 signals through the G protein-coupled chemokine receptor CXCR5 to drive development of secondary lymphoid tissue as well as B cell and Tfh cell trafficking to germinal centers (GC), which leads to the differentiation of B cells to plasma cells and memory B cells. CXCL13 has been proposed as a general plasma biomarker for GC activities. In HIV-1 infected individuals, plasma CXCL13 levels have been associated with the rate of disease progression to AIDS. Read More

View Article and Full-Text PDF
February 2021

Changes in the Incidence of Cancer in Bulawayo, Zimbabwe over a 50-Year Period.

Cancer Epidemiol Biomarkers Prev 2021 May 22;30(5):867-873. Epub 2021 Feb 22.

Zimbabwe National Cancer Registry, Parirenyatwa Group of Hospitals, Harare, Zimbabwe.

Background: The cancer registry of Bulawayo (Zimbabwe) operated for 15 years in the preindependence period (1963-77), and was restarted in 2011. This allows comparison of incidence of cancers over a period of almost 50 years.

Methods: Age-standardized rates, with SEs, were calculated for 1963-1972 and 2011-2015. Read More

View Article and Full-Text PDF

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.

J Immunother Cancer 2021 Feb;9(2)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Background: Non-Hodgkin's lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally associated with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less immunosuppressive than chemotherapy may decrease infection risk, improve immune control of oncogenic viruses, and ultimately allow for better lymphoma control. Read More

View Article and Full-Text PDF
February 2021

Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period.

Int J Hematol 2021 Feb 17. Epub 2021 Feb 17.

Fudan University (Shanghai Public Health Clinical Center), 130 Dongan Road, Xuhui District, Shanghai, 200032, China.

We investigated the clinical characteristics and outcomes of acquired immunodeficiency syndrome-related Burkitt lymphoma (AIDS-BL). A single-center retrospective study was performed of 78 cases over a 10-year period. The baseline characteristics of enrolled patients included the following: median age, 46 years; median CD4+ T lymphocyte count, 156 cells/μL; advanced stage, 74. Read More

View Article and Full-Text PDF
February 2021

A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection.

BMC Infect Dis 2021 Feb 10;21(1):165. Epub 2021 Feb 10.

Department of Radiology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.

Background: Patients with acquired immune deficiency syndrome (AIDS) often suffer from opportunistic infections and related primary central nervous system lymphoma (AR-PCNSL). Both diseases showed multiple ring enhancement lesions in conventional magnetic resonance (MR). It is very difficult to make the differential diagnosis. Read More

View Article and Full-Text PDF
February 2021

HIV-1 Tat Activates Akt/mTORC1 Pathway and AICDA Expression by Downregulating Its Transcriptional Inhibitors in B Cells.

Int J Mol Sci 2021 Feb 4;22(4). Epub 2021 Feb 4.

CNRS UMR9018, Institut Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France.

HIV-1 infects T cells, but the most frequent AIDS-related lymphomas are of B-cell origin. Molecular mechanisms of HIV-1-induced oncogenic transformation of B cells remain largely unknown. HIV-1 Tat protein may participate in this process by penetrating and regulating gene expression in B cells. Read More

View Article and Full-Text PDF
February 2021

Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma.

BMC Immunol 2021 Jan 28;22(1):10. Epub 2021 Jan 28.

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.

Background: This study investigates the effect of autologous bone marrow transfusion (BMT) on the reconstruction of both bone marrow and the immune system in patients with AIDS-related lymphoma (ARL).

Methods: A total of 32 patients with ARL participated in this study. Among them, 16 participants were treated with conventional surgery and chemotherapy (control group) and the remaining 16 patients were treated with chemotherapy followed by autologous bone marrow transfusion via a mesenteric vein (8 patients, ABM-MVI group) or a peripheral vein (8 patients, ABM-PI group). Read More

View Article and Full-Text PDF
January 2021

Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques.

JCI Insight 2021 01 11;6(1). Epub 2021 Jan 11.

Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with CCR5- donor cells is the only treatment known to cure HIV-1 in patients with underlying malignancy. This is likely due to a donor cell-mediated graft-versus-host effect targeting HIV reservoirs. Allo-HSCT would not be an acceptable therapy for most people living with HIV due to the transplant-related side effects. Read More

View Article and Full-Text PDF
January 2021

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Blood 2021 Mar;137(11):1468-1477

Mater Research Institute-University of Queensland (UQ), Brisbane, QLD, Australia.

Primary central nervous system lymphoma (PCNSL) is confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. Rarely, PCNSL occurs in the context of immunosuppression (eg, posttransplant lymphoproliferative disorders or HIV [AIDS-related PCNSL]). These cases are poorly characterized, have dismal outcome, and are typically Epstein-Barr virus (EBV)-associated (ie, tissue-positive). Read More

View Article and Full-Text PDF

Pretreatment lymphocyte-to-monocyte ratios predict AIDS-related diffuse large B-cell lymphoma overall survival.

J Med Virol 2021 06 15;93(6):3907-3914. Epub 2020 Nov 15.

Department of Infectious Diseases, Beijing You An Hospital, Beijing Institute of Hepatology, Capital Medical University, Beijing, China.

The lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been reported to be useful for predicting the prognosis of various malignancies, including diffuse large B-cell lymphoma (DLBCL). However, little is known about the role of LMR and PLR in the prognosis of DLBCL patients with human immunodeficiency virus (HIV) infection. We retrospectively evaluated the prognostic value of the LMR and PLR in patients with newly diagnosed AIDS-related diffuse large B-cell lymphoma (AR-DLBCL) who were treated with CHOP-like chemotherapy at a single institution. Read More

View Article and Full-Text PDF

Trends in the incidence of cancer in Kampala, Uganda, 1991 to 2015.

Int J Cancer 2021 May 29;148(9):2129-2138. Epub 2020 Nov 29.

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Trends in the incidence of cancer in the population of Kyadondo County, Uganda-which comprises the city of Kampala and a peri-urban hinterland-are presented for a period of 25 years (1991-2015) based on data collected by the Kampala Cancer Registry. Incidence rates have risen overall-age-adjusted rates are some 25% higher in 2011 to 2015 compared with 1991 to 1995. The biggest absolute increases have been in cancers of the prostate, breast and cervix, with rates of some 100% (prostate), 70% (breast) and 45% (cervix) higher in 2010 to 2015 than in 1991 to 1995. Read More

View Article and Full-Text PDF

Unusual disseminated Talaromyces marneffei infection mimicking lymphoma in a non-immunosuppressed patient in East China: a case report and review of the literature.

BMC Infect Dis 2020 Oct 28;20(1):800. Epub 2020 Oct 28.

PET Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P.R. China.

Background: Talaromyces marneffei infection is an important opportunistic infection associated with acquired immune deficiency syndrome (AIDS). However, it is unusual in patients with non-AIDS and other non-immunosuppressed conditions. We report a case of delayed diagnosis of disseminated T. Read More

View Article and Full-Text PDF
October 2020

[Investigation of Pneumocystis jirovecii Infection and Colonization in Immunocompromised Patients with Pneumonia].

Mikrobiyol Bul 2020 10;54(4):583-595

Mersin University Faculty of Medicine, Department of Medical Microbiology, Mersin, Turkey.

Pneumocystis jirovecii is an atypical fungus that causes P.jirovecii pneumonia (PCP) in immunocompromised patients. Currently, while the incidence of AIDS-related PCP is decreasing, PCP has become more common in HIV-negative immunosuppressive patients as a result of increased diseases requiring immunosuppressive therapy. Read More

View Article and Full-Text PDF
October 2020

Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals.

Front Oncol 2020 30;10:1723. Epub 2020 Sep 30.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States.

Epstein-Bar virus (EBV) can directly cause lymphoproliferative disease (LPD), including AIDS-defining lymphomas such as Burkitt's lymphoma and other non-Hodgkin lymphomas (NHL), as well as human immunodeficiency virus (HIV)-related Hodgkin lymphoma (HL). The prevalence of EBV in HL and NHL is elevated in HIV-positive individuals compared with the general population. Rates of incidence of AIDS-defining cancers have been declining in HIV-infected individuals since initiation of combination anti-retroviral therapy (cART) use in 1996. Read More

View Article and Full-Text PDF
September 2020

Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma.

Rep Pract Oncol Radiother 2020 Nov-Dec;25(6):956-960. Epub 2020 Oct 1.

Department of Radiation Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Objectives: Current guidelines tend to treat HIV positive (HIV+) patients as their seronegative counterparts with diffuse large B-cell lymphoma (DLBCL) but little is known about their radiotherapy responses differences.

Patients And Methods: A retrospective cohort of all consecutive HIV+ DBCL patients treated with chemotherapy between 2004 and 2018 was assessed. All patients had biopsy-proven lymphomas. Read More

View Article and Full-Text PDF
October 2020

Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development.

Rev Med Virol 2021 Mar 11;31(2):e2160. Epub 2020 Oct 11.

International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), the most common AIDS-related malignancy. It also causes other rare, but certainly underreported, KSHV-associated pathologies, namely primary effusion lymphoma, multicentric Castleman disease and KSHV inflammatory cytokine syndrome. Epidemiology and pathogenicity studies point to the potential for host genetic predisposition to KSHV infection and/or the subsequent development of KSHV-associated pathologies partly explaining the peculiar geographic and population-specific incidence of KSHV and associated pathologies and discrepancies in KSHV exposure and infection and KSHV infection and disease development. Read More

View Article and Full-Text PDF

Clinical characteristics and outcomes of HIV positive patients with lymphoma in an oncological reference center in Mexico City.

Medicine (Baltimore) 2020 Oct;99(40):e22408

Infectious Diseases Department.

The epidemiology of lymphomas has changed since the use of antiretroviral therapy. The incidence of Non-Hodgkin Lymphomas (NHL) has significantly decreased in high income countries but not in low and middle-income countries where AIDS-related events remain high. This observational study describes the characteristics, infectious complications and main outcomes of patients diagnosed with HIV and lymphoma at the Instituto Nacional de Cancerología. Read More

View Article and Full-Text PDF
October 2020

Survival of HIV-infected patients with high-grade non-Hodgkin's lymphomas: A retrospective study of experiences in Zimbabwe.

PLoS One 2020 17;15(9):e0239344. Epub 2020 Sep 17.

Center for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.

Background: Rituximab in combination with chemotherapy is now widely accepted as standard of care for AIDS-related lymphomas (ARLs) of B-cell origin. However, the clinical impact of rituximab in resource limited settings remains unknown. Different settings and patient heterogeneity may affect the effect of any given treatment. Read More

View Article and Full-Text PDF
November 2020

Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era.

Eur J Cancer 2020 10 4;138:189-192. Epub 2020 Sep 4.

Unit of Hematology-Oncology, Versailles Hospital, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Communauté Paris-Saclay, Paris, France; INSERM U1018, Centre pour La Recherche en Epidémiologie et Sante des Populations (CESP), Equipe Générations et Santé, Gustave Roussy, Villejuif, France. Electronic address:

View Article and Full-Text PDF
October 2020

Life Beyond COVID: Pay Attention to Viruses.

Int J Radiat Oncol Biol Phys 2020 10;108(2):348-350

Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

View Article and Full-Text PDF
October 2020

Treatment management of haematological malignancies in people living with HIV.

Lancet Haematol 2020 Sep 10;7(9):e679-e689. Epub 2020 Aug 10.

Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK.

Although the incidence of HIV-associated lymphomas decreased after the introduction of effective combination antiretroviral therapy, they became the most common AIDS-related cancer in high-income countries. Moreover, as people living with HIV live longer, a wide range of non-AIDS-related cancer has emerged, including other haematological malignancies. Nonetheless, combination antiretroviral therapy has offered people with HIV the opportunity to receive the same therapies as those provided to the general population, and intensive curative therapies have become the standard. Read More

View Article and Full-Text PDF
September 2020

Approach to an Intracranial Mass in Patients With HIV.

Isabel Elicer

Curr Neurol Neurosci Rep 2020 07 30;20(9):43. Epub 2020 Jul 30.

Hospital Dr. Sótero del Río, Neurology Service, Av. Concha y Toro 3459, Puente Alto, Santiago, Chile.

Purpose Of Review: Space-occupying lesions represent a diagnostic challenge among people with the human immunodeficiency virus, acquired immunodeficiency syndrome (HIV/AIDS). To determine the best diagnostic approach to the wide array of possible etiologies and provide a thorough interpretation of neuroimaging in order to narrow a hierarchical differential diagnosis among these patients. Given that there is no pathognomonic neuroimaging pattern in this clinical setting, we searched results from brain biopsies to best determine the etiology of commonly found lesions. Read More

View Article and Full-Text PDF

A Rare Case of Splenic in a HIV-Positive Patient.

Case Rep Gastrointest Med 2020 10;2020:8509591. Epub 2020 Jun 10.

Department of Medicine, BronxCare Hospital Center, Bronx, NY 10457, USA.

Introduction: Human immunodeficiency virus (HIV) positive individuals with the CD4 count less than 200 cells/mm are at risk for opportunistic infections. , a fungal pathogen, is a common cause of opportunistic infections with predominantly pulmonary involvement. Disseminated infection presenting with hepatosplenic lesion is extremely rare. Read More

View Article and Full-Text PDF

Central nervous system infiltration by HTLV-1-associated T-cell leukemia/lymphoma in an AIDS patient.

Rev Soc Bras Med Trop 2020;53:e20200060. Epub 2020 Jun 12.

Universidade Federal do Triângulo Mineiro, Hospital de Clínicas, Serviço de Hematologia e Hemoterapia, Uberaba, MG, Brasil.

View Article and Full-Text PDF
September 2020

Gastrointestinal Tract Plasmablastic Lymphoma in HIV-Infected Adults: A Histopathological Review.

Int J Surg Pathol 2020 Oct 17;28(7):735-748. Epub 2020 Jun 17.

University of the Witwatersrand, Johannesburg, South Africa.

Background.: Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma that is characterized by the expression of plasma cell antigens and loss of pan B-cell antigens. The neoplasm is extensively reported in the oral cavity and anorectal region but rarely in the gastrointestinal tract, where only isolated case reports and small case series have been reported. Read More

View Article and Full-Text PDF
October 2020

Spectrum of imaging findings in AIDS-related diffuse large B cell lymphoma.

Insights Imaging 2020 May 19;11(1):67. Epub 2020 May 19.

Aga Khan University Hospital Nairobi, 3rd Parklands Avenue, Limuru Road, Nairobi, Kenya.

Lymphoma in HIV-infected patients is AIDS defining. This is the second most common AIDS defining malignancy after Kaposi's sarcoma. Development of lymphoma in HIV patients is related to immunosuppression and high viral load. Read More

View Article and Full-Text PDF

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).

Blood 2020 09;136(11):1284-1297

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and.

EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus type-8 (HHV-8) positive. The histone deacetylase (HDAC) inhibitor vorinostat disrupts EBV/HHV-8 latency, enhances chemotherapy-induced cell death, and may clear HIV reservoirs. We performed a randomized phase 2 study in 90 patients (45 per study arm) with aggressive HIV-NHLs, using dose-adjusted EPOCH (plus rituximab if CD20+), alone or with 300 mg vorinostat, administered on days 1 to 5 of each cycle. Read More

View Article and Full-Text PDF
September 2020